LIN vs PRCT · P/E 34, rev $33.99B vs rev $224.5M
Linde plc Ordinary Shares (LIN) versus Procept Biorobotics Corp (PRCT) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Procept Biorobotics Corp (PRCT) is a medical devices company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported PRCT revenue for 2024-12-31 was $224.5M. Net income was -$91.4M. Revenue was up 64.8% from 2023-12-31 to 2024-12-31. PRCT currently screens at market cap $1.52B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. PRCT currently screens at market cap $1.52B.
Not investment advice. Open the LIN and PRCT stock pages for the full models.
Not investment advice.